RARE — ULTRAGENYX PHARMACEUTICAL IN

Ownership history in Bayesian Capital Management, LP  ·  8 quarters on record

This page tracks every 13F SEC filing in which Bayesian Capital Management, LP reported a position in ULTRAGENYX PHARMACEUTICAL IN (RARE). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price — sourced directly from SEC EDGAR 13F filings.

Peak position
0.1% (2022 Q1)
Avg. % of fund
0.07%
First filed
2019 Q1
Last filed
2025 Q3
Quarters held
8
Quarter Action Shares Change Chg % % of Fund Mkt Value Price (EOQ)
2025 Q3 REDUCED 13,100 -683 -5.0% 0.08% $394K $30.08
2025 Q1 ADDED 13,783 +5,515 +66.7% 0.08% $499K $36.21
2024 Q4 REDUCED 8,268 -5,568 -40.2% 0.04% $348K $42.07
2024 Q3 REDUCED 13,836 -1,466 -9.6% 0.09% $769K $55.55
2024 Q1 REDUCED 15,302 -961 -5.9% 0.07% $714K $46.69
2023 Q1 ADDED 16,263 +7,063 +76.8% 0.08% $652K $40.10
2022 Q1 ADDED 9,200 +5,447 +145.1% 0.10% $668K $72.62
2019 Q1 INITIATED 3,753 — — 0.05% $260K —
% of Fund (quarterly)    RARE price (monthly, adj. close)

Other funds also holding RARE

As of 2025 Q4 — sorted by position size

GordonMD Global Investments LP 5.43% B Group, Inc. 2.29% GREAT POINT PARTNERS LLC 3Y 7Y 2.24% Stonepine Capital Management, LLC 3Y 7Y 1.68% SPHERA FUNDS MANAGEMENT LTD. 3Y 7Y 1.56% Privium Fund Management B.V. 3Y 1.51% Rock Springs Capital Management LP 3Y 7Y 1.49% Palo Alto Investors LP 3Y 7Y 1.48% SPHERA FUNDS MANAGEMENT LTD. 3Y 7Y 1.34% Krensavage Asset Management, LLC 3Y 7Y 1.22%
← Back to Bayesian Capital Management, LP Holdings